問卷

TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Taichung Veterans General Hospital (在職)

Division of Thoracic Medicine

更新時間:2023-09-19

葉金水
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

50Cases

2025-04-01 - 2032-12-31

Not yet recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung

  • Test Drug

    Capsules Intravenous infusion Intravenous infusion

Participate Sites
18Sites

Recruiting18Sites

2024-01-06 - 2026-04-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting1Sites

Terminated3Sites

2017-05-01 - 2020-07-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Recruiting2Sites

Terminated8Sites

2020-01-06 - 2026-09-05

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
14Sites

Recruiting14Sites

2022-11-01 - 2025-04-14

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting8Sites

2022-11-01 - 2025-01-07

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting8Sites

2023-01-01 - 2029-05-19

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2023-11-01 - 2035-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2024-02-06 - 2029-08-30

Phase II

-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2024-06-01 - 2027-12-31

Phase I/II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

1 2 3 4 5